IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

Rhea-AI Summary

IGC Pharma (NYSE:IGC) will demonstrate its Agentic Harmonization Assistant (AHA), an AI platform for automating harmonization and analysis of complex biomedical datasets, at ADPD 2026 in collaboration with the Alzheimer's Disease Data Initiative (ADDI).

AHA targets integration of clinical trial data, imaging, and other biomedical sources to reduce manual preparation time and support development of IGC-AD1 in the Phase 2 CALMA trial.

News Market Reaction – IGC

-4.67%

1 alert

-4.67% News Effect

On the day this news was published, IGC declined 4.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Trial phase: Phase 2

1 metrics

Trial phase Phase 2 CALMA clinical trial of IGC-AD1 for agitation in Alzheimer’s disease

Market Reality Check

Price: $0.2720 Vol: Volume 347,535 is about 1...

normal vol

$0.2720 Last Close

Volume Volume 347,535 is about 1.06x the 20-day average of 328,610 shares. normal

Technical Shares at $0.289 are trading below the 200-day MA of $0.34 and 42.03% under the 52-week high.

Peers on Argus

IGC is up 3.32% while close peers like CASI (-38.97%) and LSB (-20.62%) are down...

2 Up 1 Down

IGC is up 3.32% while close peers like CASI (-38.97%) and LSB (-20.62%) are down, indicating a stock-specific move rather than a sector-wide biotech trend.

Previous AI Reports

5 past events · Latest: Feb 26 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	AI patent filing	Positive	-1.8%	Filed utility patents on AHA AI data harmonization architecture for Alzheimer’s datasets.
Nov 03	AI platform expansion	Positive	+1.8%	Expanded AI in-silico drug discovery tools for Alzheimer’s candidate identification and optimization.
Oct 22	AI prize semi-finals	Positive	-2.7%	AHA selected as semi-finalist in $1M Alzheimer’s Insights AI Prize organized by ADDI.
Jul 10	MINT-AD launch	Positive	+13.4%	Introduced MINT-AD AI diagnostic platform to predict Alzheimer’s risk and cognitive decline.
Mar 04	AI diagnostic model	Positive	-1.8%	Announced AI-driven diagnostic model integrating multi-modal data for dementia detection.

Pattern Detected

AI-related announcements have produced mixed reactions, with more instances of divergence than alignment between positive news and next-day price moves.

Recent Company History

Over the past year, IGC has repeatedly highlighted its AI strategy in Alzheimer’s, from launching diagnostic platforms like MINT-AD to expanding in‑silico discovery and advancing the AHA harmonization tool. Prior AI-tagged updates included patent filings on AHA’s architecture and recognition in the Alzheimer’s Insights AI Prize. These occurred alongside ongoing Phase 2 development of lead candidate IGC-AD1. Today’s ADPD 2026 demo with the Alzheimer’s Disease Data Initiative extends that AI narrative by emphasizing data integration and support for the CALMA trial.

Historical Comparison

+1.8% avg move · IGC’s AI-tagged news has seen an average move of 1.75%. Today’s 3.32% gain on the ADPD 2026 AHA demo...

AI

+1.8%

Average Historical Move AI

IGC’s AI-tagged news has seen an average move of 1.75%. Today’s 3.32% gain on the ADPD 2026 AHA demo sits modestly above that typical reaction range.

AI updates have progressed from launching diagnostic models and MINT-AD to prize recognition and patents for AHA, now culminating in a live ADPD 2026 demo with the Alzheimer’s Disease Data Initiative.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-12-03

An effective S-3/A resale registration dated 2025-12-03 covers up to 978,235 shares for existing holders. The company is not selling shares under this filing and will not receive proceeds, though it bears registration expenses.

Market Pulse Summary

This announcement highlights IGC’s plan to demo its AHA AI platform with the Alzheimer’s Disease Dat...

Analysis

This announcement highlights IGC’s plan to demo its AHA AI platform with the Alzheimer’s Disease Data Initiative at ADPD 2026, emphasizing automated data harmonization to support the Phase 2 CALMA trial of IGC-AD1. It extends a series of AI-driven updates around diagnostics and drug discovery. Alongside this, recent SEC filings detail new financings and an effective S-3/A resale registration. Investors may monitor AHA adoption, CALMA progress, and further capital-raising activity.

Key Terms

artificial intelligence, data harmonization, clinical trial, neurodegenerative disease, +1 more

5 terms

artificial intelligence technical

"an artificial intelligence platform designed to automate the integration and analysis"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

data harmonization technical

"AHA is an agent-based AI platform designed to harmonize fragmented datasets across"

The process of converting and aligning information from different sources into a common format and terminology so it can be accurately compared, combined, and analyzed. For investors this matters because clean, consistent data reduces mistakes and hidden risks—like translating several languages into one so a single picture or story can be reliably read—improving valuation, performance tracking, regulatory reporting, and decision-making.

clinical trial medical

"including clinical trial data, imaging, and other biomedical information."

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

neurodegenerative disease medical

"research institutions focused on accelerating discoveries in neurodegenerative disease."

Neurodegenerative disease describes a group of progressive conditions in which nerve cells in the brain and spinal cord gradually lose function and die, leading to worsening symptoms such as memory loss, impaired movement, or changes in behavior—think of it like the wiring in a house slowly corroding and causing systems to fail. It matters to investors because these illnesses drive demand for long‑term care, diagnostics, therapies and medical devices, create large commercial and regulatory risks and opportunities, and can sharply affect company valuations when clinical trial results, approvals or setbacks are announced.

Phase 2 medical

"IGC-AD1, currently being evaluated in the ongoing Phase 2 CALMA clinical trial"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. Not financial advice.

POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic Harmonization Assistant ("AHA"), an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026.

The demonstration will take place in collaboration with the Alzheimer's Disease Data Initiative (ADDI), a global data-sharing platform supported by Gates Ventures and leading research institutions focused on accelerating discoveries in neurodegenerative disease.

AHA is an agent-based AI platform designed to harmonize fragmented datasets across multiple studies, including clinical trial data, imaging, and other biomedical information. Data harmonization remains one of the most time-consuming steps in Alzheimer's research, often requiring months of manual preparation before meaningful analysis can begin. By automating this process, AHA is designed to significantly reduce the time required to prepare large datasets for analysis.

"Artificial intelligence is becoming an increasingly important component of modern biomedical research," said Ram Mukunda, CEO of IGC Pharma. "Demonstrating AHA within the ADDI ecosystem at ADPD provides an opportunity to showcase how AI-driven data integration can accelerate insights from complex datasets while strengthening our in-house analytical capabilities and advancing our clinical programs toward key milestones." Advanced data integration capabilities such as AHA may enhance analysis of complex clinical datasets and support the continued development of the Company's lead drug candidate, IGC-AD1, currently being evaluated in the ongoing Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease.

The Company also believes that scalable platforms capable of harmonizing large biomedical datasets may create future monetization opportunities to support pharmaceutical companies and global research collaborations working with complex neurodegenerative disease datasets.

Participation in ADPD reflects the Company's broader strategy of integrating artificial intelligence, advanced data analytics, and therapeutic development to accelerate innovation in Alzheimer's disease.

About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, and on Forms 10-Q filed with the SEC on August 14, 2025, and on November 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:
Walter Frank / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

What will IGC Pharma (IGC) demonstrate at ADPD 2026?

IGC will demonstrate its Agentic Harmonization Assistant (AHA) to harmonize complex biomedical datasets. According to the company, AHA automates integration across clinical trial data, imaging, and other sources to shorten manual preparation time and accelerate analysis within the ADDI ecosystem.

How does AHA aim to speed Alzheimer's research for IGC (IGC)?

AHA aims to reduce months of manual data preparation by automating harmonization steps. According to the company, automating integration across studies enables faster dataset readiness and more rapid downstream analysis supporting clinical programs like IGC-AD1.

What is the connection between AHA and IGC-AD1 development?

AHA is positioned to support analysis of complex clinical datasets relevant to IGC-AD1's Phase 2 CALMA trial. According to the company, improved data integration may strengthen in-house analytics and advance clinical milestones for the lead drug candidate.

Who is collaborating with IGC Pharma for the ADPD 2026 demonstration?

IGC is collaborating with the Alzheimer's Disease Data Initiative (ADDI) for the demonstration at ADPD 2026. According to the company, ADDI is a global data-sharing platform supported by Gates Ventures and leading research institutions.

Could AHA create commercial opportunities for IGC (IGC)?

The company believes scalable harmonization platforms may create future monetization opportunities supporting pharma and global research collaborations. According to the company, AHA's capabilities could support external partners working with complex neurodegenerative datasets.